Altered NMDA sensitivity and learning following chronic developmental NMDA antagonism.
W J Brooks, A C Weeks, J C Leboutillier, T L Petit
Physiology & Behavior November 1997 DOI: 10.1016/s0031-9384(97)00169-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Male Long-Evans rats treated developmentally from postnatal day 5 to 20 |
| Intervention | Phencyclidine (PCP) |
| Dose | 10 mg/kg |
| Duration | 15-day treatment (postnatal days 5-20), with assessments up to postnatal day 75 |
| Measures | behavioral ratings of NMDA-induced seizure activity, Morris water maze acquisition performance, initial swim heading |
| Key findings | Withdrawal from chronic developmental PCP treatment increased sensitivity to NMDA-induced seizures at 1, 5, and 15 days after the last injection and impaired Morris water maze acquisition at 3, 6, and 10 days after treatment, with less accurate initial swim headings on all test days. The authors suggest the NMDA receptor-channel complex is involved in development and learning/memory processes. |
Abstract
We have previously shown that chronic developmental administration of N-methyl-D-aspartate (NMDA) antagonists reduces synaptic development; however, on withdrawal from NMDA antagonism, there is a rebound period during which synaptogenesis exceeds control levels. The current research was undertaken to explore this period of withdrawal, using the noncompetitive antagonist phencyclidine (PCP), examining 2 behavioral measures in which the NMDA receptor is implicated: 1. NMDA-induced seizures, and 2. learning and memory in the Morris water maze. Using a protocol identical to that previously used to examine synaptic development, male Long-Evans rats were given 1 daily SC injection of either 10 mg/kg PCP or its physiological saline vehicle for a period of 15 days, beginning on postnatal Day 5 (P5) and ending on P20. Animals were then assessed for either sensitivity to NMDA-induced seizures on P21, P26, P36, or P56, or they were assessed for their acquisition performance and initial heading in the Morris water maze on P23, P26, P30, P38, and P75. Chronic treatment with PCP resulted in greater behavioral ratings of seizure activity after NMDA administration, observed 1 (P21), 5 (P26), and 15 (P36) days after the last injection of PCP, indicating increased sensitivity of the NMDA receptor/channel complex during this period after withdrawal from developmental NMDA antagonism. PCP-treated animals also required significantly more trials to reach criterion in the Morris water maze on P23, P26, and P30, and displayed significantly less accurate initial swim headings on all test days. The results are discussed in terms of the role of the NMDA receptor-channel complex in development and learning/memory processes.
Citations in the library
Cited by 4
- The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacology November 2015
- Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology July 2007
- Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochemistry International 2007
- Sustained brain-derived neurotrophic factor up-regulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. Journal of Neurochemistry November 2006
Cites 3
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
- Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science June 16, 1989
- Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior. Journal of Pharmacology and Experimental Therapeutics October 1, 1985